69 related articles for article (PubMed ID: 1462678)
21. Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect.
Dangas G; Smith DA; Unger AH; Shao JH; Meraj P; Fier C; Cohen AM; Fallon JT; Badimon JJ; Ambrose JA
Thromb Haemost; 2000 May; 83(5):688-92. PubMed ID: 10823263
[TBL] [Abstract][Full Text] [Related]
22. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients.
Castaño G; Más R; Arruzazabala ML; Noa M; Illnait J; Fernández JC; Molina V; Menéndez A
Int J Clin Pharmacol Res; 1999; 19(4):105-16. PubMed ID: 10939028
[TBL] [Abstract][Full Text] [Related]
23. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
Rouleau J
Am J Med; 2005 Dec; 118 Suppl 12A():28-35. PubMed ID: 16356805
[TBL] [Abstract][Full Text] [Related]
24. The effect of pravastatin on plasma lipoprotein and apolipoprotein levels in primary hypercholesterolemia. The Southeastern Michigan Collaborative Group.
Rubenfire M; Maciejko JJ; Blevins RD; Orringer C; Kobylak L; Rosman H
Arch Intern Med; 1991 Nov; 151(11):2234-40. PubMed ID: 1953228
[TBL] [Abstract][Full Text] [Related]
25. A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women.
Davidson MH; Testolin LM; Maki KC; von Duvillard S; Drennan KB
Arch Intern Med; 1997 Jun; 157(11):1186-92. PubMed ID: 9183229
[TBL] [Abstract][Full Text] [Related]
26. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
McKenney JM
Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
[TBL] [Abstract][Full Text] [Related]
27. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.
Franceschini G; Sirtori M; Vaccarino V; Gianfranceschi G; Chiesa G; Sirtori CR
J Lab Clin Med; 1989 Sep; 114(3):250-9. PubMed ID: 2504855
[TBL] [Abstract][Full Text] [Related]
28. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia.
Egashira K; Hirooka Y; Kai H; Sugimachi M; Suzuki S; Inou T; Takeshita A
Circulation; 1994 Jun; 89(6):2519-24. PubMed ID: 8205659
[TBL] [Abstract][Full Text] [Related]
29. Short term effects of pravastatin on blood pressure in hypercholesterolaemic hypertensive patients.
O'Callaghan CJ; Krum H; Conway EL; Lam W; Skiba MA; Howes LG; Louis WJ
Blood Press; 1994 Nov; 3(6):404-6. PubMed ID: 7704289
[TBL] [Abstract][Full Text] [Related]
30. [Effect of pravastatin on hypercholesterolemia associated with proteinuria].
Aranda Arcas JL; Sánchez R; Guijarro C; Araque A; Pulido F; Praga M; Damiano A
An Med Interna; 1994 Nov; 11(11):523-7. PubMed ID: 7654898
[TBL] [Abstract][Full Text] [Related]
31. Do statins have a specific drug effect beyond low-density lipoprotein-cholesterol-lowering in the secondary prevention of coronary artery disease?
Dohi T
Circ J; 2015; 79(1):49-50. PubMed ID: 25476194
[No Abstract] [Full Text] [Related]
32. The complex interplay between cholesterol and prostate malignancy.
Solomon KR; Freeman MR
Urol Clin North Am; 2011 Aug; 38(3):243-59. PubMed ID: 21798387
[TBL] [Abstract][Full Text] [Related]
33. Beneficial effect of cholesterol-lowering therapy on endothelium-dependent coronary vasodilation in patients with hypercholesterolemia.
Egashira K; Takeshita A
Ann N Y Acad Sci; 1995 Jan; 748():622-5. PubMed ID: 7695217
[No Abstract] [Full Text] [Related]
34. Plasma cholesterol, lipid lowering, and risk for cancer. An update of the results from epidemiologic studies and intervention trials.
Lackner KJ; Schettler G; Kübler W
Klin Wochenschr; 1989 Sep; 67(18):957-62. PubMed ID: 2677516
[TBL] [Abstract][Full Text] [Related]
35. The rapid reduction in cardiac events with lipid-lowering therapy: mechanisms and implications.
Pearson TA; Marx HJ
Am J Cardiol; 1993 Nov; 72(14):1072-3. PubMed ID: 8213589
[No Abstract] [Full Text] [Related]
36. Regression of atherosclerosis in humans by lowering serum cholesterol.
Yamamoto A
Atherosclerosis; 1991 Jul; 89(1):1-10. PubMed ID: 1772468
[No Abstract] [Full Text] [Related]
37. Remnant cholesterol in the era of intensive lipid-lowering therapies.
Wadström BN; Wulff AB; Pedersen KM; Nordestgaard BG
Eur Heart J; 2023 Sep; 44(36):3483. PubMed ID: 37322804
[No Abstract] [Full Text] [Related]
38. [The considerations on hot topics of cholesterol-lowering therapies].
Guo YF
Zhonghua Nei Ke Za Zhi; 2016 Aug; 55(8):589-91. PubMed ID: 27480549
[No Abstract] [Full Text] [Related]
39. Oxidised LDL, HDL cholesterol, LDL cholesterol levels in patients of coronary artery disease.
Ghosh J; Mishra TK; Rao YN; Aggarwal SK
Indian J Clin Biochem; 2006 Mar; 21(1):181-4. PubMed ID: 23105595
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
